Acadia Pharmaceuticals Inc. has announced that the US Food and Drug Administration has approved DAYBUE STIX, a powder version of trofinetide that can be mixed with water based liquids for patients with Rett syndrome who are two years of age or older. This new option contains no dyes or preservatives and is designed to offer the same treatment benefits as the original liquid formula while giving families more freedom to adjust dose volume and flavor according to individual needs. Acadia explained that the goal of this added formulation is to make daily treatment more manageable for both children and adults who live with the complexities of this rare neurological condition.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 5 December 2025
Catherine Owen Adams, the Chief Executive Officer of Acadia, stated that the introduction of DAYBUE STIX builds on the progress set in motion by the original DAYBUE therapy. She noted that DAYBUE has been an important therapy for many patients and that the new powder option reflects what the company has learned from families, caregivers, and clinicians who requested more flexibility in treatment routines. According to her, the company is committed to translating scientific knowledge into practical solutions that improve daily care.
Jennifer Martelle Tu, M D, Ph D,and serves as an Associate Professor of Neurology at UCSF Benioff Children’s Hospitals in Oakland, explained that the powder format will help clinicians tailor treatment more effectively. She said that caregivers can mix the powder with different water based liquids which allows them to adjust taste and volume to suit the patient. She emphasized that this type of adaptability has been an ongoing request from many families navigating Rett syndrome.
The approval of DAYBUE STIX is supported by research from the LAVENDER study which evaluated the original liquid version of DAYBUE in individuals with Rett syndrome. A bioequivalence study confirmed that the powder and the liquid forms deliver similar exposure in the body, which supports the expectation that both versions provide the same therapeutic effect and safety profile. DAYBUE STIX is expected to become available in limited quantities during the first quarter of 2026 with broader distribution planned for early in the second quarter of the same year. The current liquid form will continue to be offered.
Health Technology Insights: Daiichi Sankyo Highlights ADC Breast Cancer Trial Updates
Rett syndrome is a rare and multifaceted neurodevelopmental disorder that typically appears after a period of normal early childhood development. Symptoms begin to show between six and eighteen months of age when developmental progress slows or pauses. Children then enter a period of regression during which they may lose verbal communication skills and purposeful hand movements. Many later enter a plateau phase in which interest in surroundings may return slightly while motor function remains severely affected. Over time, individuals may experience continued motor decline. The condition usually affects girls and stems from a change in the MECP2 gene. Research suggests that reduced MeCP2 function disrupts communication between nerve cells which may contribute to many of the observed symptoms. Patients commonly develop repetitive hand movements, difficulties with walking, and other physical challenges, and most require continuous care throughout adulthood.
Trofinetide, the active ingredient in DAYBUE and DAYBUE STIX, is a laboratory developed version of a small segment of insulin like growth factor 1. Although the exact way it works in patients with Rett syndrome is not fully understood, animal studies have shown that trofinetide can increase dendritic branching and support signals related to synaptic plasticity.
DAYBUE and DAYBUE STIX are approved for adults and children who are at least two years old. The treatment carries several important safety considerations. Diarrhea is the most frequently reported issue. In clinical studies, a large majority of patients receiving DAYBUE experienced diarrhea, and roughly half had episodes that returned or persisted even with dose adjustments or antidiarrheal support. Patients should stop taking laxatives before beginning treatment and speak with their healthcare provider if diarrhea occurs. Hydration should be monitored and the dose may need to be interrupted, reduced, or stopped if severe symptoms appear or dehydration is suspected.
Vomiting is another concern. It occurred in nearly a third of patients taking DAYBUE in a twelve week study. Because people with Rett syndrome face a higher risk of aspiration and aspiration pneumonia, any vomiting should be managed carefully. Treatment may need to be paused or reduced if vomiting becomes significant. Weight loss has been reported as well, and in some cases the amount of weight lost exceeded seven percent of the patient’s baseline. Weight should be monitored and treatment may need to be adjusted if notable weight changes occur.
Other reactions that appeared more often in the treatment group than in the placebo group include fever, seizures, anxiety, reduced appetite, fatigue, and upper respiratory infections. Trofinetide may also affect how the body processes certain medications. Since it can increase the levels of drugs that depend on CYP3A or P gp pathways, clinicians should closely watch patients who are taking medicines with narrow dosing requirements. DAYBUE and DAYBUE STIX are not advised for individuals with severe kidney impairment.
Health Technology Insights: How LG Is Moving Into Clinical Workflows
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
